drugset / Trial / NCT00640588

Prospective Exploratory Study to Describe Hepatitis B Virus (HBV) Kinetics During Treatment With Telbivudine

NCT00640588

Phase 3 Completed 30 enrolled Novartis Pharmaceuticals
RandomizedSingle-groupOpen-labelOther

Summary

This study will explore HBV kinetics in CHB patients during the first 24 weeks of treatment with telbivudine

Timeline

Start
2008-03
Primary completion
2009-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Adefovir Unknown 10 mg Oral
Subject Telbivudine Small molecule 600 mg Oral